Harbour Investment Management LLC acquired a new position in Pfizer (NYSE:PFE) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 6,325 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Delphi Private Advisors LLC increased its position in shares of Pfizer by 84.3% in the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 1,600 shares in the last quarter. Americafirst Capital Management LLC purchased a new position in shares of Pfizer in the third quarter worth approximately $127,000. Oak Point Wealth Management purchased a new position in shares of Pfizer in the fourth quarter worth approximately $165,000. Cerebellum GP LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $166,000. Finally, Lipe & Dalton grew its position in Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 300 shares in the last quarter. 71.19% of the stock is currently owned by institutional investors.
NYSE PFE opened at $36.33 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $216,208.05, a price-to-earnings ratio of 13.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.90. Pfizer has a 12-month low of $31.67 and a 12-month high of $39.43.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company’s revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.47 earnings per share. analysts anticipate that Pfizer will post 2.96 EPS for the current fiscal year.
In other Pfizer news, EVP Rady A. Johnson sold 27,323 shares of Pfizer stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $36.55, for a total value of $998,655.65. Following the completion of the sale, the executive vice president now directly owns 70,332 shares in the company, valued at $2,570,634.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Douglas M. Lankler sold 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $36.89, for a total transaction of $1,844,500.00. Following the completion of the sale, the insider now owns 133,057 shares of the company’s stock, valued at $4,908,472.73. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock valued at $9,064,785 over the last quarter. Corporate insiders own 0.06% of the company’s stock.
A number of brokerages recently commented on PFE. Citigroup reaffirmed a “sell” rating on shares of Pfizer in a research report on Thursday, April 12th. Berenberg Bank reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a research report on Wednesday, April 11th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th. Jefferies Group set a $38.00 price objective on shares of Pfizer and gave the company a “hold” rating in a research report on Friday, April 13th. Finally, UBS set a $42.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $39.20.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/18/6325-shares-in-pfizer-pfe-acquired-by-harbour-investment-management-llc.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.